🤖 #ESMOAI26: Share research that translates technology into improved patient care. Submit your abstract by 1 September. 🔗 https://ow.ly/l7AC50Zl2WI #esmomeetings

⏰ There is still time to register for #MAP2026. Join the Molecular Analysis for Precision Oncology Congress, 10-11 Sept in London, for focused discussions on the latest developments in #PrecisionOncology. Late registration closes on 19 Aug 🔗 https://ow.ly/KcfU50Zw5GY #esmomeetings

📣 #ESMONovelTherapies27: Join us in Lugano for a symposium focused on the practical decisions oncologists face every day, from selecting the right treatment to preventing and managing toxicities. View the online programme. 🔗 https://ow.ly/ugKW50ZwRlW #esmomeetings

How is #immunopeptidome analysis advancing #CancerVaccine research? Juliane Walz discusses emerging strategies, from off-the-shelf to #PersonalisedVaccines, and the latest clinical evidence. #ESMODailyReporter 🔗 https://ow.ly/rckf50ZwrCb

👉 When the oncology community comes together, learning becomes stronger and new ideas emerge. Join Prof. Jeeyun Lee at ESMO Asia 2026, 4–6 December 2026 in Singapore, to connect with colleagues from across the region. Register now! 🔗 https://ow.ly/4I5I50ZuFaM #ESMOAsia26 #esmomeetings

🤖 #ESMOAI26: Join a multidisciplinary community of clinicians, researchers, engineers, data scientists and industry innovators. Submit your abstract by 1 September. 🔗 https://ow.ly/9R3a50ZhsRX #esmomeetings

👉 Present your research at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026 🔗 https://ow.ly/wKaH50ZhsKF 📍London, UK + online, 14-16 December 🗓️ Abstract deadline: 22 Sept 2026, 21:00 CEST Join the conversation on immuno-oncology and advanced therapies. #ESMOImmuno26

👉 London is the place to connect with the #PrecisionOncology community at #MAP2026, 10-11 Sept. Join peers and experts in the field for two days of focused scientific exchange. 🔗 Late registration closes on 19 Aug - secure your seat: https://ow.ly/aqAt50ZgRtZ #esmomeetings

From #ESMOGuidelines to practice: Real-world #RectalCancer cases with ESMO experts. 👉 Register now: https://ow.ly/QTag50ZjV0V #ESMOWebinars #ESMOOnAir

📣 #ESMO26: Be where the latest breakthroughs are being shared—in real time, with real impact. Last chance to register at the most advantageous fees! ⏰ Early registration deadline: 22 July 2026 🔗 https://ow.ly/ckWT50ZgSwl #esmomeetings

⏰ Last call: late registration for the #ESMOExamination 2026 closes tomorrow (21 July). Secure your seat today—registrants get exclusive access to #ESMOAcademy26 (online) to support preparation. 🔗 https://ow.ly/MVJj50ZgQXN #esmomeetings

The #ESMOGUAsia27 programme is live! 📍Hong Kong SAR, China 📅 15–17 Jan 2027 ✅ Registration open ⏳ Early deadline: 11 Nov 👉 Secure your place: https://ow.ly/eMnn50ZlY2c 🔎 View programme: https://ow.ly/Cb9V50ZlY2e #ESMOMeetings #MedOnc #RadOnc #UroSoMe

👉 ESMO Asia 2026: Your Research, Your Region, Your Impact. 🌍 Only a few days left to submit your abstract for the congress in Singapore (4–6 Dec). Turn your innovation into impact! ⏰ Deadline: Tues 21 July, 18:00 SGT / 12:00 CEST. 🔗 https://ow.ly/KACm50ZlTan #ESMOAsia26 #esmomeetings

📣 #ESMO26: The place where oncology leaders choose to share their ground-breaking studies. More than 10% increase in abstract submissions compared to 2025. ⏰ Early registration deadline: 22 July 2026 🔗 https://ow.ly/pHLe50ZgQwY #esmomeetings

ESMO welcomes the publication of WHO Global Status Report on Cancer. Recommendations closely align w/ ESMO's priorities: Comprehensive #CancerCare as part of #UHC Equitable access to high-value, patient-centred treatment & innovation Investment in the oncology workforce & cancer data systems

👉 Calling ESMO #PatientAdvocate Members across Asia-Pacific (megaphone emoji). Apply for the ESMO Patient Engagement Summit 2026 at #ESMOAsia2026 (4–6 Dec, Singapore). Connect with experts, build advocacy skills, and shape patient-centred cancer care. #PatientAdvocacy 🔗 https://ow.ly/lEA150ZkCsJ

🚀 NEW: ESMO Genitourinary Cancers Asia 2027 📢 Abstract submission is now open 📅 Deadline: 13 October 🎥 Watch the launch video & be part of the future of GU oncology. 👉 https://ow.ly/uoNo50Zk30N #ESMOMeetings #ESMOGUAsia27

🤖 #ESMOAI26 : From autonomous AI systems to real-world deployment in oncology, your work can help shape the conversation. Submit your abstract by 1 September. 🔗 https://ow.ly/miWx50ZgPnv #esmomeetings

📣 Delivering the best care means recognising the diverse needs of patients across Asia and learning from one another. Join Dr. Elaine Lim at ESMO Asia 2026, 4–6 December 2026 in Singapore. Register now to secure the best available rates! 🔗 https://ow.ly/NNs350Zjvab #ESMOAsia26 #esmomeetings

Join this session on antibody–drug conjugates and stay up to date with their clinical applications across tumour types. 👉 Register here: https://ow.ly/yeZ650ZjfvI #ESMOWebinars #ESMOOnAir #ADCs #BreastCancer #LungCancer #UrothelialCancer

📣 Continue your #ESMOGI26 experience online. Sessions with speaker permission are now available on demand on #OncologyPRO for registered delegates and ESMO members. Revisit key insights and stay connected to the latest developments in oncology. 🔗 https://ow.ly/VICO50ZkBs2 #esmomeetings

📌Looking for a recap of the congress highlights? The #ESMODailyReporter collects congress news, critical insights and expert opinions. Explore all the #ESMOGI26 content here 👇 https://ow.ly/CLn150Zk1Z1

#ESMOGI26: Encouraging data with Precem-TcT suggest that ADCs will continue to improve outcomes for patients with #GICancers, although resistance and toxicity are ongoing challenges, as discussed by Elizabeth Smyth in the #ESMODailyReporter 📌 " https://ow.ly/YBsx50Zk9XM"

#ESMOGI26: Support for #ctDNA profiling to predict survival benefits and personalise treatments is provided by two trials in patients with poor-prognosis #mCRC, as discussed by Manuel Salto-Tellez in the #ESMODailyReporter: https://ow.ly/fz1850Zk9OZ

#ESMOGI26: Adagrasib plus cetuximab failed to outperform chemotherapy in previously treated KRAS G12C-mutated #mCRC in final data from the phase III KRYSTAL-10 #ClinicalTrial. #ESMODailyReporter: https://ow.ly/5gkv50Zk2r1

#ESMOGI26: A pre-planned exploratory analysis of the phase III ATOMIC #ClinicalTrial reported no DFS benefit with the addition of immunotherapy to mFOLFOX6 in patients with dMMR #ColonCancer receiving ≤6 cycles of chemotherapy. #ESMODailyReporter ➡️https://ow.ly/OKfw50Zk2tq

#ESMOGI26: Phase III EMERALD-1 and -3 #ClinicalTrials have reported mixed results with TACE immunotherapy combinations in embolisation-eligible #HCC, with a lack of clear OS benefit and significant toxicity, despite improved PFS. #ESMODailyReporter ➡️ https://ow.ly/RuPR50ZjAzO

#ESMOGI26: Two early-phase #ClinicalTrials with zoldonrasib combinations have shown encouraging response rates in first- and second-line KRAS G12D-mutant #PancreaticCancer, as discussed by Teresa Macarulla Mercade in the #ESMODailyReporter: https://ow.ly/V6S850ZjAvt

#ESMOGI26: #mCRC tumours with no ctDNA-identified anti-EGFR resistance genes responded to continued cetuximab in the phase II CAPRI-2 #ClinicalTrial, supporting the use of #LiquidBiopsy to guide rechallenge. #ESMODailyReporter 🔗 https://ow.ly/xEZm50Zjier

👏 Congratulations to the #ESMOMeritAward recipients at #ESMOGI26. These young researchers are recognised for the scientific merit of their abstracts. 🔗 https://ow.ly/rNGg50ZjbTo #GICancers #GIOncology